Document Detail


Reversible Targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes.
MedLine Citation:
PMID:  21168488     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
AIM: Single-walled carbon nanotubes (SWNTs) have been already used as drug carriers. In this study, we introduced sgc8c aptamer (this aptamer targets leukemia biomarker protein tyrosine kinase-7) to complex between Dau (daunorubicin) and SWNT to enhance targeted delivery of Dau to acute lymphoblastic leukemia T-cells (Molt-4).
MATERIAL AND METHODS: Dau-aptamer-SWNTs tertiary complex formation was analyzed by visible spectroscopy and spectrofluorophotometric analysis. Dau release profiles from the complex were investigated in pH 7.4 and 5.5. For cytotoxic studies (MTT assay), Molt-4 (target) and U266 (B lymphocyte human myeloma, non-target) cells were treated with Dau, Dau-aptamer-SWNTs tertiary complex. Internalization was analyzed by flow cytometry. Targeted delivery of Dau was antagonized using antisense of aptamer.
RESULTS: Dau was efficiently loaded onto SWNTs (efficiency ∼157%). Dau was released from Dau-aptamer-SWNTs tertiary complex in a pH-dependent manner (higher release rate at pH 5.5). Flow cytometric analysis showed that the tertiary complex was internalized effectively to Molt-4 cells, but not to U266 cells. Cytotoxicity of Dau-aptamer-SWNTs tertiary complex also confirmed internalization data. Dau-aptamer-SWNTs tertiary complex was less cytotoxic in U266 cells when compared to Dau alone. No significant change in viability between Dau- and complex-treated Molt-4 cells was observed. Cytotoxicity of Dau-aptamer-SWNTs complex was efficiently and quickly reversed using antisense in Molt-4 cells.
CONCLUSION: Dau-aptamer-SWNTs complex is able to selectively target Molt-4 cells. The other advantages of this system are reversibility and pH-dependant release of Dau from its complex.
Authors:
Seyed Mohammad Taghdisi; Parirokh Lavaee; Mohammad Ramezani; Khalil Abnous
Related Documents :
21510778 - Cytokine secretion pattern in treatment of lymphocytes of multiple sclerosis patients w...
6461918 - Concanavalin a induces suppressor cell activity in both t gamma and t non-gamma cells: ...
6444648 - Progressive myelopathy in older german shepherd dogs. ii. presence of circulating suppr...
6216848 - Immune regulation in myasthenia gravis: evidence for an increased suppressor t-cell pop...
15030308 - Compartmentalization gamma/delta t cells and their putative role in mucosal immunity.
21255088 - Death ligand trail, secreted by cd1a+ and cd14+ cells in blister fluids, is involved in...
Publication Detail:
Type:  Journal Article     Date:  2010-12-17
Journal Detail:
Title:  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V     Volume:  77     ISSN:  1873-3441     ISO Abbreviation:  Eur J Pharm Biopharm     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9109778     Medline TA:  Eur J Pharm Biopharm     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  200-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier B.V. All rights reserved.
Affiliation:
Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Biotechnology, Mashhad University of Medical Sciences, Mashhad, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ethylene vinyl acetate as matrix for oral sustained release dosage forms produced via hot-melt extru...
Next Document:  Online monitoring of dissolution tests using dedicated potentiometric sensors in biorelevant media.